Survivors of Childhood Cancer With High Anthracycline Exposure: Can a Beta-Blocker Improve Cardiac Function?
- OPACC
- Feb 9, 2024
- 1 min read
In a U.S./Canadian phase IIb trial (PREVENT-HF) reported in The Lancet Oncology, Armenian et al found that the beta-blocker carvedilol did not significantly improve cardiac function—measured as standardized left ventricular wall thickness–dimension ratio Z score (LVWT/Dz)—vs placebo in survivors of childhood cancer with high levels of exposure to anthracyclines.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
コメント